INmune Bio
INMB
67 hedge funds and large institutions have $28.8M invested in INmune Bio in 2024 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 30 increasing their positions, 7 reducing their positions, and 7 closing their positions.
550% more call options, than puts
Call options by funds: $2M | Put options by funds: $308K
329% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 7
157% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 7
18% more funds holding
Funds holding: 57 → 67 (+10)
1.06% more ownership
Funds ownership: 23.1% → 24.15% (+1.1%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
28% less capital invested
Capital invested by funds: $40.3M → $28.8M (-$11.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PP
Praetorian PR
Rincon,
Puerto Rico
|
+$2.1M |
| 2 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
+$1.01M |
| 3 |
BlackRock
New York
|
+$900K |
| 4 |
Millennium Management
New York
|
+$781K |
| 5 |
Renaissance Technologies
New York
|
+$762K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$304K |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$256K |
| 3 |
Man Group
London,
United Kingdom
|
-$215K |
| 4 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
-$191K |
| 5 |
AGM
Alpine Global Management
New York
|
-$102K |
INMB Hedge Fund Activity: Q3 2024 in Review
67 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in INmune Bio (INMB) for Q3 2024, worth a combined $28.8M — down 28% from $40.3M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new INMB positions and 7 closed out — a net gain of 11 holders — while 30 added to existing stakes and 7 trimmed.
The largest buyer was Praetorian PR, adding an estimated $2.1M. The largest seller was Susquehanna International Group, exiting entirely with an estimated $304K sold.
- 67 institutional investors held INmune Bio (INMB) as of Q3 2024, up from 57 in Q2 2024.
- Funds reported $28.8M of INmune Bio stock for Q3 2024, down 28% quarter-over-quarter.
- 18 funds opened new INmune Bio positions in Q3 2024 and 7 closed out, a net change of +11 holders.
- The largest INmune Bio buyer in Q3 2024 was Praetorian PR, an estimated $2.1M added.
- The largest INmune Bio seller in Q3 2024 was Susquehanna International Group, an estimated $304K sold.
Based on aggregated 13F filings for Q3 2024.